Novavax Inc. (NASDAQ:NVAX) Director Gail Boudreaux bought 100,000 shares of the business’s stock in a transaction on Tuesday, September 20th. The stock was bought at an average price of $1.45 per share, with a total value of $145,000.00. Following the transaction, the director now owns 200,000 shares in the company, valued at $290,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Novavax Inc. (NASDAQ:NVAX) opened at 1.94 on Thursday. Novavax Inc. has a 52-week low of $1.16 and a 52-week high of $9.56. The firm’s market capitalization is $525.42 million. The firm has a 50-day moving average of $6.69 and a 200 day moving average of $6.16.
Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.04. Novavax had a negative net margin of 1,405.84% and a negative return on equity of 112.45%. The company earned $2.50 million during the quarter, compared to analyst estimates of $8.03 million. During the same quarter in the prior year, the firm earned ($0.08) earnings per share. Novavax’s revenue for the quarter was down 82.1% on a year-over-year basis. Analysts predict that Novavax Inc. will post ($1.09) EPS for the current year.
A number of research analysts have recently weighed in on NVAX shares. Vetr downgraded shares of Novavax from a “buy” rating to a “hold” rating and set a $7.86 price target on the stock. in a report on Tuesday, August 9th. Piper Jaffray Cos. downgraded shares of Novavax from an “overweight” rating to a “neutral” rating and cut their price target for the company from $14.00 to $1.00 in a report on Friday, September 16th. Citigroup Inc. downgraded shares of Novavax from a “buy” rating to a “neutral” rating and cut their price target for the company from $12.00 to $1.50 in a report on Friday, September 16th. Wedbush restated an “outperform” rating and set a $14.00 price target on shares of Novavax in a report on Thursday, June 2nd. Finally, FBR & Co set a $17.00 price target on shares of Novavax and gave the company a “buy” rating in a report on Thursday, August 11th. Seven equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Novavax presently has a consensus rating of “Hold” and a consensus price target of $7.06.
Several institutional investors have recently added to or reduced their stakes in the stock. Coldstream Capital Management Inc. increased its stake in shares of Novavax by 17.5% in the second quarter. Coldstream Capital Management Inc. now owns 13,805 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 2,055 shares during the last quarter. Compagnie Lombard Odier SCmA bought a new position in Novavax during the second quarter worth approximately $102,000. Veritable L.P. bought a new position in Novavax during the second quarter worth approximately $102,000. Moors & Cabot Inc. bought a new position in Novavax during the second quarter worth approximately $119,000. Finally, BlackRock Inc. boosted its position in Novavax by 138.7% in the first quarter. BlackRock Inc. now owns 19,870 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 11,547 shares during the period. Institutional investors and hedge funds own 79.84% of the company’s stock.
Novavax Company Profile
Novavax, Inc (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.